Healthy
Conditions
Brief summary
Sanquin Plasma Products BV developed a new manufacturing process for the Quin plasma products in order to improve viral safety and to remove procoagulant activity. Since the new manufacturing process will be the same for all Quin products, a clinical study with one of the Quin products is sufficient for marketing authorisation of all new Quin products. HepBQuin will serve as model for all other Quin products. Pharmacokinetic (PK) data are considered as a surrogate indicator of efficacy.
Interventions
BIOLOGICALa human hepatitis B immunoglobulin solution for injection for intramuscular administration
intramuscular administration
Sponsors
Prothya Biosolutions
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy volunteers, male and female, aged 18 to 65 inclusive. * Negative serology test for HBsAg, anti-HBs, and anti-HBc at screening. * Body-mass index (BMI) of 18.5 to 32.0 kg/m2 (inclusive). * Female volunteers must have a pregnancy test at screening. * Willing to participate by signing the written signed informed consent form.
Exclusion criteria
* Vaccinated against Hepatitis B * Having a Hepatitis B infection or suffered from a Hepatitis B infection in the past. * Known with allergic reactions against human plasma, plasma products or blood products. * A history of human immunodeficiency virus (HIV) antibody positive, or tests positive for HIV at screening. * Thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections. * Known with or having a history of arterial or venous thromboembolic events. * Pre-existing risk factors for thrombotic events. * Any clinically significant history of or current clinically significant other disease or disorder. * Any clinically significant abnormality following the investigator's review of physical examination, and clinical laboratory tests obtained at screening. * An abnormal pulse rate and/or blood pressure measurements at the screening visit. * Pregnant or breast-feeding at screening or at Day 0 * Women of childbearing potential not using a highly effective method of birth. * Any use of drugs or abuse within 3 months prior to screening and during study. * Alcohol abuse within 3 months prior to screening and during study * Participated in another interventional clinical trial a month before the start of the study, or having received an experimental drug during the previous 30 days. * Having IgA deficiency with anti-IgA antibodies. * Blood or plasma donation of more than 100 mL within 30 days prior to administration of trial medication or intended donation during the trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| half-life of anti-HBs antibodies | 84 days | Pharmacokinetics |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| number of adverse events | 84 days | Safety |
Countries
Germany
Outcome results
None listed